Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Fitxers

PIIS2468024921012791.pdf (703.64 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2021-09-01

Llicència de publicació

cc by-nc-nd (c) Buxeda, Anna et al, 2021
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/180392

Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.ekir.2021.06.023

Resum

Introduction: Remdesivir has demonstrated antiviral activity against coronavirus, shortening the time to recovery in adults hospitalized with moderate/severe COVID-19. Severe adverse events such as acute kidney injury have been reported. Scant data are available on the use and safety of remdesivir in kidney transplant recipients. Methods: We present a multicenter cohort study of 51 kidney transplant recipients with COVID-19 treated with remdesivir. Outcomes and safety were assessed. Results: Mean age at diagnosis was 60 years, with a median time since kidney transplant of 4.5 years. Mean time since admission to remdesivir was 2 days. Twenty-eight patients (54.9%) required mechanical ventilation (19 noninvasive). Mortality was 18.9% and markedly higher if aged ≥65 years (45% vs. 3.2% in younger patients). Acute kidney injury was present in 27.7% of patients, but was diagnosed in 50% before treatment. No patients required remdesivir discontinuation because of adverse events. We did not find significant hepatoxicity or systemic symptoms resulting from the drug. Conclusion: In our cohort of kidney transplant recipients, remdesivir was well tolerated and safe in renal and hepatic toxicity, but randomized trials are needed to assess its efficacy.

Matèries

SARS-CoV-2, Trasplantament renal

Matèries (anglès)

SARS-CoV-2, Kidney transplantation

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

BUXEDA, Anna, et al. Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19. Kidney International Reports. 2021. Vol. 6, num. 9, pags. 2305-2315. ISSN 2468-0249. [consulted: 4 of August of 2026]. Available at: https://hdl.handle.net/2445/180392

Exportar metadades

JSON - METS

Compartir registre